News - PharmaCyte Biotech

- 08 SEP 2021
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
LAGUNA HILLS, CA, September 8, 2021 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held
Read more →
- Posted in
- News
- 31 AUG 2021
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
LAGUNA HILLS, CA, August 31, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing
Read more →
- Posted in
- News
- 25 AUG 2021
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
LAGUNA HILLS, CA, August 25, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company will expand its product pipeline to again include its diabetes program and its malignant ascites program.
Read more →
- Posted in
- News
- 23 AUG 2021
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company’s common stock
Read more →
- Posted in
- News
- 19 AUG 2021
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
LAGUNA HILLS, CA, August 19, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct
Read more →
- Posted in
- News
- 16 AUG 2021
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
LAGUNA HILLS, CA, August 16, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, regarding the Company’s recent listing on Nasdaq
Read more →
- Posted in
- News
- 12 AUG 2021
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced underwritten public offering of approximately $15 million. The public offering includes 3,529,412 shares of the Company’s
Read more →
- Posted in
- News
- 09 AUG 2021
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company’s common stock is expected to begin trading on The Nasdaq Capital Market on August 10, 2021, under the symbol
Read more →
- Posted in
- News
- 02 AUG 2021
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company’s common stock on Nasdaq. The Company’s common stock
Read more →
- Posted in
- News
- 22 JUL 2021
PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment
LAGUNA HILLS, CA, July 22, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that three independent industry publications mention PharmaCyte and/or its past clinical trials and their contributions to prior and future work
Read more →
- Posted in
- News

Press Releases